These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28002471)

  • 21. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
    Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
    Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of omeprazole on gastro-oesophageal reflux and symptoms during strenuous exercise.
    Peters HP; De Kort AF; Van Krevelen H; Akkermans LM; Van Berge Henegouwen GP; Bol E; Mosterd WL; De Vries WR
    Aliment Pharmacol Ther; 1999 Aug; 13(8):1015-22. PubMed ID: 10468675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux.
    Moore DJ; Tao BS; Lines DR; Hirte C; Heddle ML; Davidson GP
    J Pediatr; 2003 Aug; 143(2):219-23. PubMed ID: 12970637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux.
    Robinson M; Maton PN; Allen ML; Humphries TJ; McIntosh D; Cagliola AJ; Bradstreet TE
    Aliment Pharmacol Ther; 1991 Dec; 5(6):645-51. PubMed ID: 1782307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
    Wo JM; Koopman J; Harrell SP; Parker K; Winstead W; Lentsch E
    Am J Gastroenterol; 2006 Sep; 101(9):1972-8; quiz 2169. PubMed ID: 16968502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empiric therapy for gastroesophageal reflux disease.
    Schindlbeck NE; Klauser AG; Voderholzer WA; Müller-Lissner SA
    Arch Intern Med; 1995 Sep; 155(16):1808-12. PubMed ID: 7654116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rectal Omeprazole in Infants With Gastroesophageal Reflux Disease: A Randomized Pilot Trial.
    Bestebreurtje P; de Koning BAE; Roeleveld N; Knibbe CAJ; Tibboel D; van Groen B; van de Ven CP; Plötz FB; de Wildt SN
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):635-643. PubMed ID: 32594305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux.
    Ferrari M; Benini L; Brotto E; Locatelli F; De Iorio F; Bonella F; Tacchella N; Corradini G; Lo Cascio V; Vantini I
    Scand J Gastroenterol; 2007 Mar; 42(3):299-307. PubMed ID: 17354108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination drug therapy for gastroesophageal reflux disease.
    Cross LB; Justice LN
    Ann Pharmacother; 2002 May; 36(5):912-6. PubMed ID: 11978171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.
    Wo JM; Grist WJ; Gussack G; Delgaudio JM; Waring JP
    Am J Gastroenterol; 1997 Dec; 92(12):2160-5. PubMed ID: 9399745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.
    Kierkus J; Furmaga-Jablonska W; Sullivan JE; David ES; Stewart DL; Rath N; Fu C; Wang W; Maguire MK; Comer GM
    Dig Dis Sci; 2011 Feb; 56(2):425-34. PubMed ID: 20607405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gastric acid suppression of a new oral powder omeprazole suspension for infants with gastroesophageal reflux disease. A pilot study].
    Orsi M; Donato G; Busoni V; Naisberg G; Caruso N
    Acta Gastroenterol Latinoam; 2011 Jun; 41(2):111-8. PubMed ID: 21894724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
    Katzka DA; Paoletti V; Leite L; Castell DO
    Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?
    Madsen LG; Wallin L; Bytzer P
    Aliment Pharmacol Ther; 2004 Aug; 20(4):423-30. PubMed ID: 15298636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.
    Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L
    Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
    Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
    Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study.
    Laursen LS; Havelund T; Bondesen S; Hansen J; Sanchez G; Sebelin E; Fenger C; Lauritsen K
    Scand J Gastroenterol; 1995 Sep; 30(9):839-46. PubMed ID: 8578181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].
    Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA
    Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.